WallStSmart

Monster Beverage Corp (MNST)vsPfizer Inc (PFE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Pfizer Inc generates 654% more annual revenue ($62.58B vs $8.29B). MNST leads profitability with a 23.0% profit margin vs 12.4%. MNST appears more attractively valued with a PEG of 2.13. MNST earns a higher WallStSmart Score of 68/100 (B-).

MNST

Strong Buy

68

out of 100

Grade: B-

Growth: 8.0Profit: 9.5Value: 8.7Quality: 7.8
Piotroski: 5/9Altman Z: 5.91

PFE

Hold

49

out of 100

Grade: D+

Growth: 2.0Profit: 6.5Value: 4.7Quality: 4.8
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MNSTUndervalued (+11.0%)

Margin of Safety

+11.0%

Fair Value

$90.79

Current Price

$73.21

$17.58 discount

UndervaluedFair: $90.79Overvalued
PFESignificantly Overvalued (-194.9%)

Margin of Safety

-194.9%

Fair Value

$9.25

Current Price

$27.28

$18.03 premium

UndervaluedFair: $9.25Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MNST6 strengths · Avg: 9.5/10
Operating MarginProfitability
31.3%10/10

Strong operational efficiency at 31.3%

EPS GrowthGrowth
66.6%10/10

Earnings expanding 66.6% YoY

Altman Z-ScoreHealth
5.9110/10

Safe zone — low bankruptcy risk

Market CapQuality
$71.62B9/10

Large-cap with strong market position

Return on EquityProfitability
26.8%9/10

Every $100 of equity generates 27 in profit

Profit MarginProfitability
23.0%9/10

Keeps 23 of every $100 in revenue as profit

PFE4 strengths · Avg: 8.3/10
Market CapQuality
$153.36B9/10

Large-cap with strong market position

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

Operating MarginProfitability
23.9%8/10

Strong operational efficiency at 23.9%

Free Cash FlowQuality
$4.50B8/10

Generating 4.5B in free cash flow

Areas to Watch

MNST3 concerns · Avg: 4.0/10
PEG RatioValuation
2.134/10

Expensive relative to growth rate

P/E RatioValuation
37.7x4/10

Premium valuation, high expectations priced in

Price/BookValuation
8.7x4/10

Trading at 8.7x book value

PFE4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
13.772/10

Expensive relative to growth rate

Revenue GrowthGrowth
-1.2%2/10

Revenue declined 1.2%

EPS GrowthGrowth
-21.3%2/10

Earnings declined 21.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : MNST

The strongest argument for MNST centers on Operating Margin, EPS Growth, Altman Z-Score. Profitability is solid with margins at 23.0% and operating margin at 31.3%. Revenue growth of 17.6% demonstrates continued momentum.

Bull Case : PFE

The strongest argument for PFE centers on Market Cap, Price/Book, Operating Margin.

Bear Case : MNST

The primary concerns for MNST are PEG Ratio, P/E Ratio, Price/Book.

Bear Case : PFE

The primary concerns for PFE are Piotroski F-Score, PEG Ratio, Revenue Growth.

Key Dynamics to Monitor

MNST profiles as a growth stock while PFE is a declining play — different risk/reward profiles.

MNST carries more volatility with a beta of 0.44 — expect wider price swings.

MNST is growing revenue faster at 17.6% — sustainability is the question.

PFE generates stronger free cash flow (4.5B), providing more financial flexibility.

Bottom Line

MNST scores higher overall (68/100 vs 49/100), backed by strong 23.0% margins and 17.6% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Monster Beverage Corp

CONSUMER DEFENSIVE · BEVERAGES - NON-ALCOHOLIC · USA

Monster Beverage Corporation is an American beverage company that manufactures energy drinks including Monster Energy, Relentless and Burn.

Visit Website →

Pfizer Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.

Visit Website →

Want to dig deeper into these stocks?